Table 2.
Comparison of nevirapine-derived pharmacokinetic parameters between our study and previous studies of children
| Parameter [median (range)] | Present study | Previous paediatric studies | |
|---|---|---|---|
| Chokephaibulkit et al. 34 | Pollock et al. 14 | ||
| Number of children | 94 | 34 | 25 |
| Age (years) | 7.2 (0.17–17.5) | 8.4 (3–15) | 6.3 (0.8–16) |
| Bodyweight (kg) | 21 (2.9–67) | — (4–40) | 15.9 (6.3–38.9) |
| Daily dose | 200 (40–400) mg | 328 (244–435) mg m−2 | 250 (100–400) mg |
| CL (l h−1 kg−1) | 0.08 (0.03–0.14) | 0.08 (0.02–0.16) | 0.1 (0.03–0.18) |
| AUC0–12 (mg h−1 l−1) | 65.3 (25–191) | 78.4 (50–307) | 79.9 (44–146) |
| Cmin (mg−1 l−1) | 4.3 (1.3–14.2) | 5.98 (2.57–24.4) | 5.9 (2.3–9.1) |
Abbreviations are as follows: CL, clearance; AUC0-12, area under the concentration-time curve from 0 to 12 h; Cmin, minimal concentration.